About US
Contact us
>>Back
Bayer and Onyx restructure oncology collaboration
- Publisher：
- Publication：2011/10/18
Bayer HealthCare and Onyx Pharmaceuticals have restructured their oncology partnership relating to the medication Nexavar and late-stage compound regorafenib.
As per the revised agreement, Nexavar will remain largely unchanged with both companies free to market the drug; however, Bayer will purchase Onyx's royalty rights for the sale of the drug in Japan as of 1 January 2012.
Bayer will also retain final decision-making for the global development and commercialisation of regorafenib, whereas Onyx will receive royalties based on future sales of the compound.
The revised collaboration agreement also settles all claims filed by Onyx against Bayer, which go back to May 2009.